王氏保赤丸联合双歧杆菌三联活菌治疗便秘型肠易激综合征的疗效观察

Clinical Efficacy of Wangshi Baochi Pill Combined with Bifidobacterium Triple Viable in Treatment of Constipation Type of Irritable Bowel Syndrome

目的:探讨王氏保赤丸联合双歧杆菌三联活菌胶囊治疗便秘型肠易激综合征(IBS-C)的临床疗效和安全性。方法:选取2022年5月至2023年5月,本院收治的68例IBS-C患者,随机分为治疗组和对照组,每组各34例。治疗组采用王氏保赤丸联合双歧杆菌三联活菌胶囊口服治疗,对照组采用双歧杆菌三联活菌胶囊口服治疗,连续治疗2周,观察2组总有效率,治疗前后粪便性状积分、腹痛腹胀积分和不良反应情况。结果:治疗组总有效率为91.1%,高于对照组的70.5%(P<0.05)。治疗后,治疗组粪便性状和腹痛积分均优于对照组(P<0.05);2组腹胀积分比较,差异无统计学意义(P>0.05)。治疗过程中2组均未有不良反应发生。结论:王氏保赤丸联合双歧杆菌乳杆菌三联活菌胶囊口服治疗IBS-C临床疗效较好,且安全性高,值得临床推广应用。

Objective To investigate the clinical efficacy and safety of Wangshi Baochi Pill combined with bifidobacterium triple viable capsule in the treatment of constipation type of irritable bowel syndrome(IBS-C).Methods Total 68 patients with IBS-C admitted to our hospital from May 2022 to May 2023 were randomly divided into treatment group and control group,with 34 cases in each group.The treatment group was treated with Wangshi Baochi Pill combined with bifidobacterium triple viable capsule orally,while the control group was treated with bifidobacterium triple viable capsule orally for 2 weeks continu-ously.The total effective rate,fecal trait scores,abdominal pain and abdominal distension scores before treatment and adverse reactions of the two groups were observed.Results The total effective rate was 91.1%in the treatment group,which was higher than 70.5%in the control group(P<0.05).After treatment,fecal trait and abdominal pain scores in the treatment group were better than those in the con-trol group(P<0.05).There was no significant difference in abdominal distension scores between the two groups(P>0.05).No adverse reactions occurred in both groups during treatment.Conclusion Wangshi Baochi Pill combined with bifidobacterium triple viable capsule for the treatment of IBS-C has good clinical efficacy and high safety,which is worthy of clinical promotion and application.